Nektar Therapeutics
Income Statement
| Line Item | FY2009 |
|---|---|
| Revenue | $71.9M |
| Cost of Revenue | $30.9M |
| Gross Profit | $41.0M |
| Gross Margin | 57.0% |
| Operating Expenses | |
| Research & Development | $95.1M |
| SG&A Expense | $41.0M |
| Operating Income | $-95.1M |
| Operating Margin | -132.3% |
| Interest Expense | $12.2M |
| Pretax Income | $-102.8M |
| Income Tax Expense | $-253.0K |
| Net Income | $-102.5M |
| Net Margin | -142.5% |
| EPS (Basic) | $-1.11 |
| EPS (Diluted) | $-1.11 |
| Shares Outstanding (Basic) | — |
| Shares Outstanding (Diluted) | — |
| Dividends Per Share | — |